Location & dates EMBL Heidelberg, Germany 4 - 6 Dec 2016
Deadlines Registration closed Abstract submission closed
organiser_WGC

Conference Programme

Day 1 - Sunday 4 December 2016
TimeSpeaker
13.00 - 15:00 Registration and Lunch
15.00 - 18.00 Session 1 Human based drug discovery  Chair: Jeff Barrett, Open Targets, United Kingdom
15:00 - 15:15 Opening remarks
15:15 - 16:15

Keynote Speaker
A Drug Hunter’s Perspective – Translational Challenges in Drug Discovery
Tony Wood - Pfizer, United States of America

16:15 - 16:45

The target landscape of clinical kinase drugs
Bernhard Küster - Technical University of Munich, Germany

16:45 - 17.15

Coffee Break

17.15 - 17.45 Using WES to identify new drug targets: putting it all together
Frederick Dewey - Regeneron Genetics Center, United States of America
17.45 - 18.00 Improving Target Identification and Prioritisation through Open Targets : an Integrated Programme of Experiments and Bioinformatics
Ian Dunham - EMBL-EBI, United Kingdom
18.00 - 18.15 Functional dissection of breast cancer risk-associated TERT  promoter variants
Sonja Helbig - Hannover Medical School, Germany
18.15 - 20.00 Poster session 1 Odd Numbers, ATC Foyer
20.00 - 21.00 Gala Dinner, EMBL Canteen
21.00 - 24.00 Welcome session with Glühwein, Roof Top Lounge
Day 2 - Monday 5 December 2016
TimeSpeaker
09.00 - 12.00

Session 2 Genetics at scale : GWAS, PheWas and Populations

Chair: Sally John, Biogen, USA

09.00 - 09.30 MALDI mass spectrometry biotyping and imaging for studies of target activation and drug response distribution
Carsten Hopf - Mannheim University of Applied Sciences, Germany
09.30 - 09.45 Lower Age-At-Onset (AAO) in Multiple Sclerosis (MS) is Associated with the HLA-DQA1*05/HLA-DQB1*06:02 Cis- or Trans- Heterodimer
Paola Bronson - Biogen, Inc., United States of America
09.45 - 10.00 Developing solutions to support human genomics and translational data discovery, access and sharing
Serena Scollen - ELIXIR, United Kingdom
10.00 - 10.30

Proteomic Target Validation of the Clinical PDE10A Inhibitor MP-10 Demonstrates Target Engagement and Exquisite Selectivity.
Jan Schuelke, Evotec GmbH, Germany

10.30 - 11.00 Coffee break
11.00 - 11.30 Patient derived  iPSCs  and phenotypic screens to identify novel mechanism in amyotrophic lateral sclerosis
Siddharthan Chandran - University of Edinburgh, United Kingdom
11.30 - 11.45 Meta-analysis of exome array data identifies seven novel lung function loci
Victoria Jackson, University of Leicester, United Kingdom
11.45 - 12.00 Predicting efficacy and safety of genetic drug targets through meta-analysis of several “Real World Data” cohorts
Dorothée Diogo - Merck Research Laboratories, United States of America
12.00 - 14.00 Lunch

Session 3 High content phenotyping and system biology

Chair: Ewan Birney EMBL-EBI, United Kingdom

14.00 - 14.30

The US precision medicine initiative and identifying new drug targets
Teri Manolio - National Human Genome Research Institute, United States of America

14.30 - 15.00 Systems biology of cell division using light microscopy
Jan Ellenberg - EMBL Heidelberg, Germany
15.00 - 15.15 Network-based in silico target identification and validation
Krol Aram - Euretos, The Netherlands
15.15 - 15.30 Gene prioritization & target selection by multidimensional scoring
Eric Simon - Boehringer Ingelheim Pharma GmbH & Co KG Germany
15.30 - 15.45 Coffee Break
15.45 - 16.15 Using insights from human genome-phenome associations across 684 studies, 549 phenotypes and 2.7 million individuals in drug discovery and development
Ciara Vangeli - Genomics Plc, United Kingdom
16.15 - 16.30

Finding potential Therapeutic targets against Shigella flexneri through druggable genome exploration
Mohammed Hossain - Mawlana Bhashani Science and Technology University - Bangladesh

16.30 - 16.45 Metabolomic Screening of Cholesterol Lowering Targets: Comprehensive Metabolic Effects of Statins, Ezetimibe and PCSK9-inhibition Assessed via Genetic Evidence in 30,000 individuals
Peter Würtz - University of Oulu, Finland               
16.45 - 17.00 Pan-cancer genomic and transcriptomic profiling of immune checkpoint genes reveals disease segments with potential therapeutic relevance for immunotherapy selection
Maria Secrier - AstraZeneca, United Kingdom
17.00 - 17.15 Discovery and characterisation of inhibitors of the Mediator complex-associated kinases CDK8 and CDK19 using proteomics, transcriptomics and CRISPR approaches
Paul Clarke - Institute of Cancer Research, United Kingdom
17.15 - 19.00 Poster session 2: Even numbers
19.15 Buses depart to Christmas market
Day 3 - Tuesday 6 December 2016
TimeSpeaker
09.00 - 12.00

Session 4 Analytical Methods

Chair: Mike Ferguson, University of Dundee, United Kingdom

09:00 - 09:30

Chemical Proteomics in Drug Discovery
Gitte Neubauer - Cellzome GmbH, Germany

09:30 - 10.00

Disease trajectories, gene pleiotropy and protein multi-functionality
Søren Brunak - Novo Nordisk Foundation Center for Protein Research, Denmark

10:00 - 10:15 A statistical framework for generating effective therapeutic hypotheses from human genetic data
Manuel Rivas - Stanford University United States of America
10:15 - 10:45 Coffee Break
10:45 - 11.00 Scoring gene-disease targets and computational integration of diverse evidence types
Oliver Stegle - EMBL-EBI United Kingdom
11.00 - 11.15

LiMMBo: Linear Mixed Model Bootstrapping. A method to handle 100s of phenotypes in multi-trait mapping
Hannah Meyer - EMBL-EBI, United Kingdom

11:15 - 11:30

Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance and genes underlying this link
Robert Scott - GSK, United Kingdom

11:30 - 11:45 In-silico identification of new potential indications for Dupilumab using a molecular signature
Frank Staubli - Nebion AG, Switzerland
11:45 - 12:00 Break
12:00 - 14:15

Session 5: Genomics

Chair: Serena Scollen, ELIXIR, United Kingdom

12:00 - 12:30

A Systems Approach to Reverse Engineer Lifespan Extension by Dietary Restriction
Jing-Dong Jackie Han - Chinese Academy of Sciences, China

12:30 - 13.30

Keynote Speaker
Impact of Genetic Variation on Type 2 Diabetes Risk, Diagnosis and Complications in Ancestrally Diverse Populations

Inês Barroso - Wellcome Trust Sanger Institute, United Kingdom

13.30 - 13:45 Poster prize and closing ceremony
13:45 Takeaway Lunch bags
14.00 Buses depart to all hotels and Frankfurt International Airport